FINWIRES · TerminalLIVE
FINWIRES

加拿大皇家银行表示,收购 Comerica 后,第五三银行有望实现稳定增长。

-- 加拿大皇家银行资本市场(RBC Capital Markets)周一通过电子邮件发布的一份报告称,在首席执行官蒂姆·斯宾塞(Tim Spence)的领导下,五三银行(Fifth Third Bancorp,股票代码:FITB)凭借其稳健的资本纪律和对康美银行(Comerica)的成功收购,已做好实现“稳定盈利”增长的准备,这将为股东的长期价值奠定基础。 该机构表示,此次交易完成时未造成任何“有形账面价值稀释”,并补充说,每股有形账面价值环比增长1.2%,同比增长15%,达到22.88美元。报告指出,此次合并使五三银行的总资产立即突破3000亿美元大关。 报告称,虽然公布的每股收益0.15美元受到一次性合并相关费用的影响,但调整后的每股收益0.83美元反映了合并后业务的“潜在盈利能力”。 该机构指出,市场整合工作进展顺利,预计将在劳动节周末完成全面的“系统转换”。报告称,该银行管理层预计到2026年将实现3.6亿美元的“净成本节约”,并补充说,该银行在德克萨斯州的发展势头尤为强劲,客户响应率是传统市场的三倍。 加拿大皇家银行维持对五三银行(Fifth Third Bancorp)的“跑赢大盘”评级,目标价为57美元。

Price: $50.90, Change: $+0.56, Percent Change: +1.11%

Related Articles

Asia

National Australia Bank Shares Down After Resolution of Union Court Proceedings

National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."

$ASX:NAB
Asia

Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant

Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.

$ASX:CUV
Asia

XRF Scientific Completes Acquisition of Combustion Gas Analysis Business

XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.

$ASX:XRF